BeOne Medicines
↗Basel, Switzerland (redomiciled May 2025); originally Cambridge, Massachusetts
BeOne Medicines, formerly BeiGene Ltd., is a multinational oncology-focused biopharmaceutical company headquartered in Cambridge, Massachusetts with operations spanning 45+ countries across six continents. The company rebranded from BeiGene to BeOne Medicines in November 2024 and redomiciled to Basel, Switzerland in May 2025, marking a strategic shift in its global positioning. With approximately 11,000-12,000 employees and a robust R&D team of 1,200+, BeOne is one of the most productive oncology pipelines in the industry with 40+ clinical and commercial-stage assets. The company achieved its first year of profitability in 2025 with $5.3 billion in global revenue, making it the highest-revenue Chinese-originated biotech company in history.
CLASSIFICATION
SIZE & FINANCIALS
Employees:10000+
Revenue:$5.3B (2025)
Founded:2010
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:N/A - Public company
Investors:Various institutional investors; publicly traded
STOCK
Exchange:NASDAQ, HKEX, SSE
Ticker:ONC (NASDAQ; changed January 2025), 06160 (HKEX), 688235 (SSE)
Market Cap:Estimated $50B+ based on 2025 performance
PIPELINE
Stage:Commercial and Clinical (Phase 1-3)
Lead Drug Stage:Brukinsa (zanubrutinib) - Approved; Tevimbra (tislelizumab) - Approved; Sonrotoclax - Phase 3 (FDA Priority Review)
Modalities:Small molecule inhibitors, Monoclonal antibodies, Checkpoint inhibitors (PD-1), Bispecific antibodies, Antibody-drug conjugates (ADC), BCL-2 inhibitors, Protein degraders, Cytokine therapy, Cell therapy
Active Trials:175
Trial Phases:Phase 1: 15 | Phase 2: 35 | Phase 3: 25 | Phase 4: 10
FDA Approvals:17
EMA Approvals:8
CORPORATE STRUCTURE
Subsidiaries:BeOne Medical Affairs, BeOne Medical Information, BeOne Clinical Trials operations
Key Partnerships:Amgen - Collaboration on oncology pipeline, Bristol Myers Squibb (BMS) - Strategic partnership, Novartis - Collaboration on cancer treatments, Biocytogen - Antibody licensing agreement (July 2025), Senhwa Biosciences - Clinical supply agreement for Pidnarulex + Tislelizumab combination, Multiple academic and research institutions
COMPETITION
Position:Leader
Competitors:Roche/Genentech, Merck, Bristol Myers Squibb, Novartis, Eli Lilly, Gilead Sciences, Incyte Corporation, Janssen Pharmaceuticals +1 more
LEADERSHIP
Key Executives:
John V. Oyler - Chief Executive Officer and Chairman
Xiaodong Wang - Co-Founder; Scientific Leadership
Aaron Rosenberg - Senior Executive
Xiaobin Wu - Senior Executive
Scientific Founders:Xiaodong Wang
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of BeOne Medicines and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with BeOne Medicines. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.